Thursday 12 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%

Follow INCY

Alert me

Market cap: $24.9B
P/E: 58.1×
Fwd P/E: 57.3×
Dividend yield: —
F-score: 9/9
ROIC: 21.6%
Net debt / EBITDA: −2.2×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation (INCY) P/E ratio

Alert me on P/E ratio

As of 12 November 2026, Incyte Corporation (INCY) trades at a P/E ratio of 58.1×. Over the past ten years it has ranged from 0.0× (March 2021) to 5,423× (December 2015); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 11.2× and above the Healthcare sector median of 24.6×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/pe-ratio">Incyte Corporation (INCY) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	15.0×	(93.28%)
FY2024	223×	808.93%
FY2023	24.5×	(52.55%)
FY2022	51.7×	201.91%
FY2021	17.1×	—
FY2020	0.0×	—
FY2019	42.0×	(65.67%)
FY2018	122×	—
FY2017	0.0×	—
FY2016	183×	(96.63%)

Period	P/E ratio	Change
Sep 2026	57.8×	314.69%
Jun 2026	13.9×	8.15%
Mar 2026	12.9×	(13.85%)
Dec 2025	15.0×	7.99%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 5,423×

Ten-year median 20.3×

Current reading's percentile 65

Company	P/E ratio
ROIV Roivant Sciences Ltd. compare	n/m
INSM Insmed, Inc. compare	n/m
BNTX BioNTech SE Sponsored ADR compare	n/m
ALNY Alnylam Pharmaceuticals, Inc. compare	7.9×
ASND Ascendis Pharma A/S compare	19.3×
EXEL Exelixis, Inc. compare	20.2×
GMAB Genmab A/S Sponsored ADR compare	44.0×
INCY Incyte Corporation	58.1×
JAZZ Jazz Pharmaceuticals PLC compare	66.5×
Biotechnology industry median	11.2×
Healthcare sector median	24.6×
Market median	17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Incyte Corporation (INCY) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on INCY

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on INCY

Stockrow Weekly